BML-280

• UNSPSC Description:

  BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].

• Target Antigen:

  Interleukin Related; Phospholipase; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease

• Field of Research:

  Cancer; Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bml-280.html

• Purity:

  99.64

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC2=CC=CC=C2N=C1)NCCN(CC3)CCC3(N(C4=CC=CC=C4)CN5)C5=O

• Molecular Weight:

  429.51

• References & Citations:

  [1]Burkhardt U, et al. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. |[2]Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257.|[3]Tsai YR, et al. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):507-19.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1158347-73-9